Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Sarcoma 1Lymphoma 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 4fludarabine phosphate 3fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Cytarabine 2Azacitidine 2venetoclax 1thymoglobulin 1tazemetostat 1romidepsin 1quizartinib 1plerixafor 1glucarpidase 1cc-486 1capmatinib 1aldesleukin 1Zoledronic Acid 1Vincristine 1Transplantation 1Thiotepa 1Spironolactone 1Rituximab 1Rifampin 1Pravastatin 1Polymerase Chain Reaction 1Palliative Care 1Methotrexate 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Spironolactone × Sarcoma × Clear all
NCT04190433 2023-05-24

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Mayo Clinic

Phase 2 Withdrawn
BreastLymphoidOther hematologic neoplasmSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡